MedTrace Logo

Phase II Avastin Trial for Stage IIIB/IV NSCLC

NCT00766246 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2016-04-19

No results posted yet for this study

Summary

This is a randomized, open-label, multicenter study in 160 patients in first line treatment and 114 in second line treatment with advanced or metastatic NSCLC (Stage IIIB/IV).

Conditions

  • Non-small Cell Lung Cancer Stage IIIB
  • Non-small Cell Lung Cancer Stage IV

Interventions

DRUG

bevacizumab

15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance

DRUG

docetaxel

75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment

DRUG

carboplatin

AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Sanofi

    collaborator INDUSTRY

  • Pharmatech

    lead INDUSTRY

Principal Investigators

  • Chandra P Belani, MD · Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Penn State Hershey Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2012-04-30
Completion
2012-04-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00766246 on ClinicalTrials.gov